Showing results (71-80 of 160) with videos related to

Sort By:
Pageof 16
The Journal of Antimicrobial Chemotherapy|April 30, 2025
Activity of rezafungin against Candida aurisJeffrey B Locke, David Andes, Shawn Flanagan, et al.
Open Forum Infectious Diseases|April 6, 2026
Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized TrialsLuis Ostrosky-Zeichner, Jalal A Aram, Mark Redell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2010
Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern eraJ Ryan Bariola, Paul Perry, Peter G Pappas, et al.
Antimicrobial Agents and Chemotherapy|February 25, 2005
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitisRobert A Larsen, Peter G Pappas, John Perfect, et al.
Infection Control and Hospital Epidemiology|January 4, 2008
Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis Douglas C Chang, Lauren A Burwell, G Marshall Lyon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 22, 2014
Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases GroupRaoul Herbrecht, Thomas F Patterson, Monica A Slavin, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2023
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris<i>:</i> Results from a Phase 2 TrialJose A Vazquez, Peter G Pappas, Kenneth Boffard, et al.
Open Forum Infectious Diseases|August 6, 2020
Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19George R Thompson Iii, Oliver A Cornely, Peter G Pappas, et al.
Clinical Epidemiology|September 2, 2024
Epidemiology of Invasive CandidiasisDerek J Bays, Emily N Jenkins, Meghan Lyman, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2019
MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasisAndrej Spec, John Pullman, George R Thompson, et al.
Pageof 16